

CV Date	20/07/2022
----------------	------------

Part A. PERSONAL INFORMATION

First Name	Jerónimo		
Family Name	Pachón Díaz		
Sex	Male	Date of Birth	09/05/1948
ID number Social Security, Passport	28377156D		
URL Web			
Email Address	pachon@us.es		
Open Researcher and Contributor ID (ORCID)	0000-0002-8166-5308		

A.1. Current position

Job Title	Emeritus Professor of University		
Starting date	2018		
Institution	University of Seville		
Department / Centre	Medicine / School of Medicine		
Country	Spain	Phone Number	
Keywords	Antibiotics; Clinical medicine; Therapeutics		

A.2. Previous positions (Research Career breaks included)

Period	Job Title / Name of Employer / Country
1998 - 2018	Jefe de Servicio Enfermedades Infecciosas / Hospital Universitario Virgen del Rocío
2012 - 2014	Director General de Calidad, Investigación, Desarrollo e Innovación. / Consejería de Igualdad, Salud y Políticas Sociales. Junta de Andalucía.

A.3. Education

Degree/Master/PhD	University / Country	Year
Doctor en Medicina y Cirugía	Universidad de Sevilla / Spain	1974
Licenciado en Medicina y Cirugía	Universidad de Sevilla / Spain	1971

Part B. CV SUMMARY

Head of the research group "Infectious Diseases" at the Institute of Biomedicine of Seville, University Hospital Virgen del Rocío/CSIC/University of Seville and the Andalusian R+D+I Plan (PAIDI CTS-203) from 1986 to 2021.

Research lines: i) Infections in immunosuppressed patients; ii) Viral infections; iii) Microbial resistance; iv) Nonantimicrobial approaches for difficult-to-treat infections; v) New antibiotics and antivirals.

Author in 372 scientific manuscripts; Total citations without self-citations 14.853; Index h: 65. Sixteen patents of intellectual or industrial property, 2 licensed and 3 internationals.

Co-founder of spin-off biotechnology company Vaxdyn S.L. in 2011.

Director of 38 Doctoral Theses.

Award 2012: Fama-University of Seville, Spain.

Award 2010: Moreno López, Spanish Society of Infectious Diseases and Clinical Microbiology, 2010, Spain.

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Most important publications in national or international peer-reviewed journals, books and conferences

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- 1 **Scientific paper.** Tania; Gema; Marta; Jeronimo; María Eugenia. (6/8). 2022. IgM-enriched immunoglobulin improves colistin efficacy in a pneumonia model by *Pseudomonas aeruginosa* Life Science Alliance. 5-10, pp.e202101349.
- 2 **Scientific paper.** Cristina; Judith; Pedro; Jeronimo; Javier. (14/18). 2022. Excretion and viability of SARS-CoV-2 in feces and its association with the clinical outcome of COVID-19 Scientific Reports. 12-1, pp.7397.
- 3 **Scientific paper.** María Luisa; Jeronimo; Younes. (2/3). 2022. iTRAQ-Based Quantitative Proteomic Analysis of *Acinetobacter baumannii* under Hypoxia and Normoxia Reveals the Role of OmpW as a Virulence Factor Microbiology Spectrum. 10-2, pp.e0232821.
- 4 **Scientific paper.** Sonsoles; Zaira; José Ramón; Jesús; Jeronimo. (10/10). 2021. Impact of early interferon- β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort Biomedicine and Pharmacotherapy. 146, pp.112572.
- 5 **Scientific paper.** Jose; Enrique; Julia; Jeronimo; José Miguel. (18/23). 2021. SHORTEN trial team. Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial Clinical Microbiology and Infection. 28-4, pp.550-557.
- 6 **Scientific paper.** S Salto-Alejandre; J Berastegui-Cabrera; P Camacho-Martínez; JM Cisneros; J Pachon; E Cordero; J Sánchez-Céspedes. 2021. SARS-CoV-2 viral load in nasopharyngeal swabs is not an independent predictor of unfavorable outcome Scientific Reports. 11-1, pp.12931. <https://doi.org/10.1038/s41598-021-92400-y>
- 7 **Scientific paper.** S Salto-Alejandre; S Jiménez-Jorge; N Sabé; J Pachon; J Sánchez-Céspedes; E Cordero. 2021. Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: A prospective multicenter cohort study Plos One. 16, pp.e0250796. <https://doi.org/10.1371/journal.pone.0250796>
- 8 **Scientific paper.** T Cebrero-Cangueiro; G Labrador-Herrera; A Pascual; et al;. 2021. Efficacy of Fosfomicin and Its Combination With Aminoglycosides in an Experimental Sepsis Model by Carbapenemase-Producing *Klebsiella pneumoniae* Clinical Strains Front Med (Lausanne). 8, pp.615540. <https://doi.org/10.3389/fmed.2021.615540>
- 9 **Scientific paper.** J Berenguer; AM Borobia; P Ryan; et al;. 2021. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score Thorax. Epub ahead of print. <https://doi.org/10.1136/thoraxjnl-2020-216001>
- 10 **Scientific paper.** B Gutiérrez-Gutiérrez; MD del Toro; AM Borobia; et al;. 2021. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study Lancet Infect Dis. Epub ahead of print. [https://doi.org/10.1016/S1473-3099\(21\)00019-0](https://doi.org/10.1016/S1473-3099(21)00019-0)
- 11 **Scientific paper.** S Fontserè; C Infante-Domínguez; A Suárez-Benjumea; et al;. 2021. Impact of Treating Asymptomatic Bacteriuria in Kidney Transplant Recipients: A Prospective Cohort Study Antibiotics (Basel). 10, pp.218. <https://doi.org/10.3390/antibiotics10020218>
- 12 **Scientific paper.** T Cebrero-Cangueiro; P Nordmann; M Carretero-Ledesma; J Pachon; ME Pachon-Ibañez. 2021. Efficacy of dual carbapenem treatment in a murine sepsis model of infection due to carbapenemase-producing *Acinetobacter baumannii* J Antimicrob Chemother. 76, pp.680-683. <https://doi.org/10.1093/jac/dkaa487>
- 13 **Scientific paper.** G Labrador-Herrera; AJ Perez-Pulido; R Álvarez-Marín; et al;. 2020. Virulence role of the outer membrane protein CarO in carbapenem-resistant *Acinetobacter baumannii* Virulence. 11, pp.1727-1737. <https://doi.org/10.1080/21505594.2020.1855912>

- 14 **Scientific paper.** J Berastegui-Cabrera; S Salto-Alejandre; M Valerio; J Pachon; JM Cisneros; E Cordero; J Sánchez-Céspedes. 2020. SARS-CoV-2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load *Journal of Infection*. 82, pp.e38-e41. <https://doi.org/10.1016/j.jinf.2020.11.024>
- 15 **Scientific paper.** S Salto-Alejandre S; C Roca-Oporto; J Pachon; JM Cisneros. 2020. A quick prediction tool for unfavourable outcome in COVID-19 inpatients: Development and internal validation *Journal of Infection*. 82, pp.e11-e15. <https://doi.org/10.1016/j.jinf.2020.09.023>
- 16 **Scientific paper.** S Mazzotta; T Cebrero-Cangueiro; L Frattaruolo; et al;. 2020. Exploration of piperazine-derived thioureas as antibacterial and anti-inflammatory agents. In vitro evaluation against clinical isolates of colistin-resistant *Acinetobacter baumannii* *Bioorg Med Chem Lett*. 30, pp.127411. <https://doi.org/10.1016/j.bmcl.2020.127411>
- 17 **Scientific paper.** J Rodríguez-Baño; J Pachon; J Carratalà; P Ryan; I Jarrin; M Yllescas; JR Arribas; J Berenguer. 2020. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19) *Clin Microbiol Infect*. 27, pp.244-252. <https://doi.org/10.1016/j.cmi.2020.08.010>
- 18 **Scientific paper.** J Berenguer; P Ryan; J Rodríguez-Baño; I Jarrin; J Carratalà; J Pachon; M Yllescas; JR Arriba. 2020. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain *Clin Microbiol Infect*. 26, pp.1525-1536. <https://doi.org/10.1016/j.cmi.2020.07.024>
- 19 **Scientific paper.** María Luisa Gil Marqués; Gema Labrador Herrea; Andrea Miro Canturri; Jerónimo Pachón; Younes Smani; María Eugenia Pachón Ibáñez. 2020. Role of PstS on the pathogenesis of *Acinetobacter baumannii* under microaerobiosis and normoxia *Journal of Infectious Diseases*. 222, pp.1204-1212. <https://doi.org/10.1093/infdis/jiaa201>
- 20 **Scientific paper.** J Sánchez Céspedes; JA Marrugal Lorenzo; C Martin Gandul; et al;. 2020. T-cells immune response controls the high incidence of adenovirus infection in adult allogenic hematopoietic transplantation recipients *Haematologica*. 106, pp.275-278. <https://doi.org/10.3324/haematol.2019.240101>
- 21 **Scientific paper.** S Mazzotta; JA Marrugal-Lorenzo; M Vega-Holm; et al;. 2020. Optimization of piperazine-derived ureas privileged structures for effective antiadenovirus agents. *Eur J Med Chem*. 185, pp.111840. <https://doi.org/10.1016/j.ejmech.2019.111840>
- 22 **Scientific paper.** EL Mangas; A Rubio; R Álvarez-Marín; G Labrador-Herrera; J Pachón; ME Pachón-Ibáñez; F Divina; AJ Pérez-Pulido. 2019. Pangenome of *Acinetobacter baumannii* uncovers two groups of genomes, one of them with genes involved in CRISPR/Cas defence systems associated with the absence of plasmids and exclusive genes for biofilm formation *Microbial Genomics*. 5-11, pp.e000309.
- 23 **Scientific paper.** Marrugal-Lorenzo JA; Serna-Gallego A; Berastegui-Cabrera J; Pachón J; Sánchez-Céspedes J. 2019. Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections. *Sci Rep*.9(1):17.
- 24 **Scientific paper.** Cebrero-Cangueiro T; Álvarez-Marín R; Labrador-Herrera G; Smani Y; Cordero-Matía E; Pachón J; Pachón-Ibáñez ME. 2018. In vitro Activity of Pentamidine Alone and in Combination With Aminoglycosides, Tigecycline, Rifampicin, and Doripenem Against Clinical Strains of Carbapenemase-Producing and/or Colistin-Resistant Enterobacteriaceae *Front Cell Infect Microbiol*.18;9:363.
- 25 **Scientific paper.** Vila-Farrés X; Parra-Millén R; Sánchez-Encinales V; et al; Smani Y. 2017. Combating virulence of Gram-negative bacilli by OmpA inhibition. *Scientific Reports*. Oct 31;7(1), pp.14683.
- 26 **Scientific paper.** Pachón-Ibáñez ME; Smani Y; Pachon J; Sánchez-Céspedes J. 2017. Perspectives for clinical use of engineered human host defense antimicrobial peptides *FEMS Microbiol Rev* 2017. 41-(3), pp.323-342.
- 27 **Scientific paper.** Sánchez-Céspedes J; Martínez-Aguado P; Vega-Holm M; Serna-Gallego A; Candela JI; Marrugal-Lorenzo JA; Pachon J. 2016. New 4-Acyl-1-phenylaminocarbonyl-2-phenylpiperazine Derivatives as Potential Inhibitors of Adenovirus Infection. Synthesis, Biological Evaluation, and Structure-activity Relationships. *Journal of Medicinal Chemistry*. 59-11, pp.5432-5448.

28 Scientific paper. Vila-Farrés X; López-Rojas R; Pachón-Ibáñez ME; Teixidó M; Pachón J; Vila J; Giralt E. 2015. Sequence-activity relationship, and mechanism of action of mastoparan analogues against extended-drug resistant *Acinetobacter baumannii* Eur J Med Chem. 101, pp.34-40.

C.3. Research projects and contracts

- 1 Project.** Desarrollo y validación de nuevas tecnologías diagnósticas, detección de multirresistencia y de determinantes de virulencia, de manera precoz, en las bacteriemias por *Pseudomonas aeruginosa*. Instituto de Salud Carlos III. María Eugenia Pachón Ibáñez. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 01/01/2021-31/12/2023. 98.010 €.
- 2 Project.** Uso de agentes anti-cancerígenos como estrategia antimicrobiana para el tratamiento de las infecciones por bacilos gramnegativos. Institute of Health Carlos III. Manuel Enrique Jiménez Mejías. (Institute of Biomedicine of Seville). 01/01/2020-31/12/2022. 123.420 €.
- 3 Project.** Evaluación, in vitro e in vivo, de la eficacia de pentamidina asociada a otros antimicrobianos en el tratamiento de enterobacterias productoras de carbapenemasas o resistentes a colistina. Institute of Health Carlos III. Rocío Álvarez Marín. (Institute of Biomedicine of Seville). 01/11/2019-31/12/2021. 178.172,5 €.
- 4 Project.** Estudio de la carga viral de SARS-CoV-2 en vías respiratorias y sangre como factor asociado al pronóstico de la COVID-19 en adultos (COVID_CV).. Instituto de Salud Carlos III. Javier Sánchez Céspedes. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 30/04/2020-29/10/2021. 189.765 €.
- 5 Project.** Multicenter study of coronavirus disease 2019 (COVID-2019) in Solid Organ Transplant Recipients (COVIDSOT, GESITRA/REIPI). Instituto de Salud Carlos III. María Elisa Cordero Matía. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 30/04/2020-29/10/2021. 182.201 €.
- 6 Project.** (DTS17/00130) Nuevos compuestos innovadores derivados de piperazina para el tratamiento de infecciones causadas por virus oportunistas. Javier Sánchez Céspedes. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 01/01/2017-31/12/2019. 33.550 €.

C.4. Activities of technology / knowledge transfer and results exploitation

- 1** Sanchez Céspedes 1; Cordero Matia 2; Berastegui Cabrera 3; Pachon Ibáñez 4; Pachon 5; Balsera 6; Carretero 7. EP22382139.8. Microsomes: cellular like structures to control viral infections (MICROTRAPS) Spain. 18/02/2022. Servicio Andaluz de Salud y Universidad de Sevilla.
- 2** Jia Xhou; Jerónimo Pachón Díaz; Judith Berastegui Cabrera; María Eugenia Pachón Ibáñez; Javier Sánchez Céspedes; Jimin Xu. 46855. Salicylamide derivativs and related methods of making United States of America. 26/01/2020. University of Texas, USA. Servicio Andaluz de Salud, Andalucía, Spain. University of Seville, Spain.
- 3** Jerónimo Pachón Díaz; José Antonio Lepe Jiménez; Ángel Rodríguez Villodres; Younes Smani. P201930573. Kit y método de detección rápida de bacterias resistentes a las combinaciones de antibióticos betalactámicos con inhibidores de b-lactamasas, y de la resistencia de espectro extendido a los betalactámicos en aislados clínicos Spain. 21/06/2019. University of Seville and Servicio Andaluz de Salud.
- 4** Javier Sánchez Céspedes; María Eugenia Pachón Ibáñez; Jerónimo Pachón Díaz; Pablo Martínez Aguado; Tania Cebrero Cangueiro; José Manuel Vega Pérez; Fernando Iglesias Guerra; Margarita Vega Holm; José Ignacio Candela Lena; Sarah Mazzota. PCT/EP2017/054252. Piperazine derivatives as antiviral agents with increased therapeutic activity Spain. 23/08/2018. University of Seville and Servicio Andaluz de Salud.
- 5** Javier Sánchez Céspedes; Jerónimo Pachón Díaz; Pablo Martínez Aguado; María Eugenia Pachón Ibáñez; Tania Cebrero; José Manuel Vega; Fernando Iglesias; Margarita Vega; José Ignacio Candela; Sarah Mazzotta. EP16382073.1. Piperazine derivatives as antiviral agents with increased therapeutic activity 23/02/2016. Servicio Andaluz de Salud and University of Seville.